EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease

Viswanath Devanarayan iD, Thomas Doherty, Arnaud Charil, Pallavi Sachdev, Yuanqing Ye, Leema Krishna Murali, Daniel A Llano, Jin Zhou, Larisa Reyderman, Harald Hampel, Lynn D Kramer, Shobha Dhadda und 1 weitere

Alzheimer's & Dementia · 2024-08 · 20 (8) · 5617-5628

DOI: 10.1002/alz.14073 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 28.06.2024. Verfasst von Viswanath Devanarayan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Eisai Inc., Clinical Evidence Generation, Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Brain, Positron-Emission Tomography. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND This study investigated the potential of phosphorylated plasma Tau217 ratio (pTau217R) and plasma amyloid beta (Aβ) 42/Aβ40 in predicting brain amyloid levels measured by positron emission tomography (PET) Centiloid (CL) for Alzheimer's disease (AD) staging and screening. METHODS Quantification of plasma pTau217R and Aβ42/Aβ40 employed immunoprecipitation‐mass spectrometry. CL prediction models were developed on a cohort of 904 cognitively unimpaired, preclinical and early AD subjects and validated on two independent cohorts. RESULTS Models integrating pTau217R outperformed Aβ42/Aβ40 alone, predicting amyloid levels up to 89.1 CL. High area under the receiver operating characteristic curve (AUROC) values (89.3% to 94.7%) were observed across a broad CL range (15 to 90). Utilizing pTau217R‐based models for low amyloid levels reduced PET scans by 70.5% to 78.6%. DISCUSSION pTau217R effectively predicts brain amyloid levels, surpassing cerebrospinal fluid Aβ42/Aβ40's range. Combining it with plasma Aβ42/Aβ40 enhances sensitivity for low amyloid detection, reducing unnecessary PET scans and expanding clinical utility. CLINICALTRIALS.GOV IDENTIFIERS NCT02956486 (MissionAD1), NCT03036280 (MissionAD2), NCT04468659 (AHEAD3‐45), NCT03887455 (ClarityAD) Highlights Phosphorylated plasma Tau217 ratio (pTau217R) effectively predicts amyloid‐PET Centiloid (CL) across a broad spectrum. Integrating pTau217R with Aβ42/Aβ40 extends the CL prediction upper limit to 89.1 CL. Combined model predicts amyloid status with high accuracy, especially in cognitively unimpaired individuals. This model identifies subjects above or below various CL thresholds with high accuracy. pTau217R‐based models significantly reduce PET scans by up to 78.6% for screening out individuals with no/low amyloid.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesBrainPositron-Emission Tomographytau ProteinsAgedFemaleHumansMaleMiddle AgedBiomarkersCohort StudiesPeptide FragmentsPhosphorylationClinical Trials as Topic

Stichwörter der Autor:innen

blood‐based biomarkersdiagnosisdisease continuumdisease stagingpatient monitoringpatient screeningprediction

Substanzen

Amyloid beta-Peptidesamyloid beta-protein (1-40)BiomarkersPeptide Fragmentstau Proteins

Autor:innen und Institutionen

  • Eisai Inc., Clinical Evidence Generation, Nutley, New Jersey, USA.
  • Department of Mathematics, Statistics and Computer Science, University of Illinois Chicago, Chicago, Illinois, USA.
  • Eisai Ltd., Clinical Evidence Generation, Hatfield, UK.
  • Carle Illinois College of Medicine, Urbana, Illinois, USA.
  • Department of Molecular and Integrative Physiology, University of Illinois Urbana-Champaign, Urbana, Illinois, USA.
  • Beckman Institute for Advanced Science and Technology, Urbana, Illinois, USA.

ORCID-Profile: Viswanath Devanarayan

Förderung

  • Eisai Inc.

Zitieren

APA

Devanarayan, V., Doherty, T., Charil, A., Sachdev, P., Ye, Y., Murali, L. K., Llano, D. A., Zhou, J., Reyderman, L., Hampel, H., Kramer, L. D., Dhadda, S., & Irizarry, M. C. (2024). Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimer's & Dementia, 20(8), 5617-5628. https://doi.org/10.1002/alz.14073

Vancouver

Devanarayan V, Doherty T, Charil A, Sachdev P, Ye Y, Murali LK, et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimer's & Dementia. 2024;20(8):5617-5628. doi:10.1002/alz.14073

BibTeX
@article{Devanarayan2024,
  author = {Devanarayan, Viswanath and Doherty, Thomas and Charil, Arnaud and Sachdev, Pallavi and Ye, Yuanqing and Murali, Leema Krishna and Llano, Daniel A and Zhou, Jin and Reyderman, Larisa and Hampel, Harald and Kramer, Lynn D and Dhadda, Shobha and Irizarry, Michael C},
  title = {Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {8},
  pages = {5617--5628},
  doi = {10.1002/alz.14073}
}
Kostenlos starten →